What's Next for Hims & Hers Health, Inc. Shareholders After 14.73% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline

Complaint alleges Hims & Hers Health, Inc. misled investors between August 4, 2025 and July 29, 2026; investors may seek lead plaintiff role by November 2, 2026

LOS ANGELES, Oct. 20, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP ("Glancy") announced today that the class action lawsuit covers investors who bought Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) securities between August 4, 2025 and July 29, 2026. The Hims & Hers Health, Inc. case, Velanki v. Hims & Hers Health, Inc., et al., was filed on September 1, 2026 in the U.S. District Court for the Northern District of California (Case No. 3:26-cv-09313).

Investors who suffered losses on Hims & Hers Health, Inc. investments can submit their Hims & Hers Health, Inc. loss information here before the November 2, 2026 lead plaintiff deadline.

Key dates in the Hims & Hers Health, Inc. case

• Class period: August 4, 2025 to July 29, 2026
• Complaint filed: September 1, 2026
• Lead plaintiff deadline: November 2, 2026

What happened?

On July 29, 2026, the Federal Trade Commission, joined by the State of Utah and Los Angeles County (representing California), filed a federal complaint against Hims & Hers Health in the U.S. District Court for the Northern District of California, alleging deceptive and unlawful privacy practices — including sharing sensitive user health data with third-party advertisers Meta Platforms (Facebook) and Snap via embedded tracking pixels and customer list matching despite marketing emphasizing strict privacy — as well as deceptive billing and subscription-cancellation practices.

On this news, shares of Hims & Hers fell $4.32, or 14.73%, to close at $25.00 per share on July 29, 2026, thereby injuring investors.

What is the Hims & Hers Health, Inc. lawsuit about?

The Hims & Hers Health, Inc. securities lawsuit alleges that, between August 4, 2025 and July 29, 2026, defendants made materially false and/or misleading statements and failed to disclose material adverse facts about Hims & Hers Health, Inc.'s business, operations, and prospects. Specifically, the complaint alleges defendants failed to disclose that: (1) the Company shared consumers' health information with third-party advertising platforms; (2) the Company charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is "right for them"; (3) the foregoing conduct subjected the Company to regulatory scrutiny; (4) as a result of the foregoing, the Company was reasonably likely to incur fees and penalties; and (5) as a result, defendants' positive statements about Hims & Hers Health, Inc.'s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

"The complaint filed against Hims & Hers Health, Inc. alleges that, among other things, the Company failed to disclose that the Company shared consumers' health information with third-party advertising platforms. For investors who bought during the class period, the November 2, 2026 deadline is the first major step in this case," said Charles H. Linehan, Partner at Glancy Prongay Wolke & Rotter LLP.

What's the next step?

Glancy Prongay Wolke & Rotter LLP is a leading national shareholder rights law firm, ready to assist Hims & Hers Health, Inc. investors in potentially pursuing claims to recover their losses.

If you wish to serve as lead plaintiff in the Hims & Hers Health, Inc. class action, you must move the Court no later than November 2, 2026. To learn more about your rights, visit the Hims & Hers Health, Inc. case page, email [email protected], or call 310-201-9150 (toll-free: 888-773-9224).

You may retain counsel of your choice. If you bought Hims & Hers Health, Inc. securities during the class period, you may take no action and remain an absent class member. No class has been certified yet in the Hims & Hers Health, Inc. case.

Frequently Asked Questions

Who is eligible? Investors who purchased or otherwise acquired Hims & Hers Health, Inc. securities between August 4, 2025 and July 29, 2026 and suffered losses may be members of the proposed class in the Hims & Hers Health, Inc. shareholder lawsuit. Any class member may ask the court to appoint them lead plaintiff by November 2, 2026.

What is a lead plaintiff? In the Hims & Hers Health, Inc. class action, the lead plaintiff is the investor, or group of investors, that the court appoints to represent all class members and oversee the case. Under the Private Securities Litigation Reform Act, courts generally presume the movant with the largest financial interest is the most adequate lead plaintiff.

Do I have to be lead plaintiff to recover? No. A Hims & Hers Health, Inc. investor's ability to share in any future recovery does not depend on serving as lead plaintiff. Hims & Hers Health, Inc. investors may take no action and remain absent class members.

What is the deadline? Motions to serve as lead plaintiff in the Hims & Hers Health, Inc. class action must be filed by November 2, 2026.

Does it cost anything to contact Glancy or participate in this action? Glancy represents Hims & Hers Health, Inc. investors on a contingency fee basis, which means investors pay no attorneys' fees unless there is a recovery. Any fees are subject to court approval and are paid from the recovery.

Can I choose my own lawyer? Yes. Hims & Hers Health, Inc. investors may retain counsel of their choice.

Why work with Glancy on the Hims & Hers Health, Inc. lawsuit? Glancy Prongay Wolke & Rotter LLP is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Contact Glancy about the Hims & Hers Health, Inc. lawsuit. Prior results do not guarantee a similar outcome.

About Glancy Prongay Wolke & Rotter LLP

Glancy was named one of Law360's Securities Groups of the Year and ranked second in total investor recoveries by ISS Securities Class Action Services in 2025.

Glancy's successes have been widely covered by leading news and industry publications, including The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money.

Prior results do not guarantee a similar outcome.

Related links

• Hims & Hers Health, Inc. case page, Glancy Prongay Wolke & Rotter LLP
• Complaint: Velanki v. Hims & Hers Health, Inc., et al., U.S. District Court for the Northern District of California
• FTC complaint
• Hims & Hers Health, Inc. SEC filings index, EDGAR
• Glancy Prongay Wolke & Rotter LLP

Contact
Charles H. Linehan
Glancy Prongay Wolke & Rotter LLP
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
Email: [email protected] 
Telephone: 310-201-9150 | Toll-free: 888-773-9224
www.glancylaw.com
Follow Glancy on LinkedIn, X, or Facebook.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

SOURCE Glancy Prongay Wolke & Rotter LLP